“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

BioLineRx


BioLineRx products

Aphexda®

  • Generic: motixafortide

  • Indication: Mobilization of hematopoietic stem cells (in combination with filgrastim) for peripheral blood collection ahead of autologous stem cell transplantation in multiple myeloma patients.

  • Dose / Usage: Administered by subcutaneous injection after approximately four days of filgrastim; typical dose ~1.25 mg/kg given 10–14 hours before apheresis.

BL-8040 (motixafortide)

  • Not a separate marketed product but the same molecule behind Aphexda®, being advanced in other investigational applications, such as pancreatic cancer and sickle cell disease.

AGI-134

  • Generic: AGI-134

  • Indication: Investigational immunotherapy (anti-cancer vaccine) targeting solid tumors.

  • Status / Usage: Currently in preclinical or early-stage clinical development under investigational new drug (IND) status; no approved dosing yet.



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)